Patient - Page - About - Patient Experience

Results from clinical studies

Enjoying a walk with a dog

During development, Lazanda was studied in over 46,000 experiences of breakthrough cancer pain (BTPc) among 523 patients (over 150,000 BTPc experiences during development and the long-term extension study combined).1,2 Some of these patients were treated for more than 2 years.1

Here are some of the results of the clinical studies:

Side effects

  • Patients taking Lazanda did not have any major nasal side effects2
  • Overall, side effects that patients did have were those that typically happen with many types of opioid therapy. The most common of these, occurring in 5% or more of patients taking Lazanda, were1:
    • Nausea
    • Vomiting
    • Dizziness

These are not all the possible side effects of Lazanda. Be sure to tell your healthcare provider if you have any side effect that bothers you or does not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also report side effects to Depomed by calling 1-866-458-6389.

Ease of use

  • 90% of Lazanda patients were satisfied or very satisfied with the ease of use of Lazanda for up to 97% of BTPc episodes*3

Convenience

  • 90% of Lazanda patients were satisfied or very satisfied with the convenience of Lazanda for up to 98% of BTPc episodes*3

You may also be glad to know that you may eat and drink before and after taking Lazanda, since it is absorbed through your nasal passages and not your mouth.

90% satisfaction

Important Safety Information

Always keep Lazanda in a safe place away from children and from anyone for whom it has not been prescribed. Lazanda can cause life-threatening breathing problems that can lead to death.

  • *Study description:
    An extension study conducted at several U.S. clinics in which both the researchers and patients knew whether Lazanda or placebo was given. The study was designed to assess the safety and tolerability of Lazanda in 356 patients taking around-the-clock opioid therapy for persistent cancer pain who were having 1 to 4 daily episodes of moderate to severe BTPc.